{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:20:34Z","timestamp":1792016434923,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.seizure.2018.10.016","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T12:12:36Z","timestamp":1540555956000},"page":"17-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["The pharmacological management of Lennox-Gastaut syndrome and critical literature review"],"prefix":"10.1016","volume":"63","author":[{"given":"Alberto","family":"Verrotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Iapadre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zagaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-0081","authenticated-orcid":false,"given":"Giangennaro","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriano","family":"Mecarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Franzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola De","family":"Liso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-0051","authenticated-orcid":false,"given":"Federico","family":"Vigevano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Curatolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.seizure.2018.10.016_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fneur.2017.00505","article-title":"Expert opinion on the management of lennox-gastaut syndrome: treatment algorithms and practical considerations","volume":"29","author":"Cross","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2018.10.016_bib0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","article-title":"Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology","volume":"8","author":"Arzimanoglou","year":"2009","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10072-017-3188-y","article-title":"Lennox-Gastaut syndrome: a comprehensive review","volume":"39","author":"Asadi-Pooya","year":"2018","journal-title":"Neurol Sci"},{"issue":"Suppl 5","key":"10.1016\/j.seizure.2018.10.016_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.03177.x","article-title":"Definition and natural history of Lennox-Gastaut syndrome","volume":"52","author":"Camfield","year":"2011","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2018.10.016_bib0025","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1528-1167.2008.01944.x","article-title":"Lennox-Gastaut syndrome with late-onset and prominent reflex seizures in trisomy 21 patients","volume":"50","author":"Ferlazzo","year":"2009","journal-title":"Epilepsia"},{"issue":"7466","key":"10.1016\/j.seizure.2018.10.016_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12439","article-title":"De novo mutations in epileptic encephalopathies. Epi4K consortium; epilepsy Phenome\/Genome project","volume":"501","author":"Allen","year":"2013","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2018.10.016_bib0035","first-page":"S3","article-title":"All children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome\u2026 but many do","volume":"13","author":"Arzimanoglou","year":"2011","journal-title":"Epileptic Disord"},{"issue":"2","key":"10.1016\/j.seizure.2018.10.016_bib0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000052108","article-title":"Eating seizures in Lennox-Gastaut syndrome","volume":"45","author":"Lee","year":"2001","journal-title":"Eur Neurol"},{"key":"10.1016\/j.seizure.2018.10.016_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2017.09.006","article-title":"Lennox-Gastaut syndrome in adulthood: long-term clinical follow-up of 38 patients and analysis of their recorded seizures","volume":"77","author":"Vignoli","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.10.016_bib0050","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1469-8749.1988.tb04782.x","article-title":"The Lennox-Gastaut syndrome","volume":"30","author":"Livingston","year":"1988","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"10.1016\/j.seizure.2018.10.016_bib0055","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.seizure.2011.08.001","article-title":"An atypical case of Lennox-Gastaut syndrome not associated with mental retardation: a nosological issue","volume":"20","author":"Shyu","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.10.016_bib0060","article-title":"Psychiatric and Behavioural Disorders in Children with Epilepsy (ILAE Task Force Report): behavioural and psychiatric disorders associated with childhood epilepsy syndromes","author":"Besag","year":"2016","journal-title":"Epileptic Disord"},{"issue":"Suppl 5","key":"10.1016\/j.seizure.2018.10.016_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.03177.x","article-title":"Definition and natural history of Lennox- Gastaut syndrome","volume":"52","author":"Camfield","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0070","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1684\/epd.2017.0934","article-title":"Atlas of electroencephalography, 3rd edition","volume":"19","author":"Asadi-Pooya","year":"2017","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2018.10.016_bib0075","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00004691-200311000-00005","article-title":"Lennox-Gastaut syndrome (Childhood epileptic encephalopaty)","volume":"20","author":"Markand","year":"2003","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.seizure.2018.10.016_bib0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1684\/epd.2017.0952","article-title":"The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 2)","volume":"4","author":"Koutroumanidis","year":"2017","journal-title":"Epileptic Disord"},{"issue":"7","key":"10.1016\/j.seizure.2018.10.016_bib0085","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e3182a08f6a","article-title":"Networks underlying paroxysmal fast activity and slow spike and wave in Lennox-Gastaut syndrome","volume":"81","author":"Pillay","year":"2013","journal-title":"Neurology"},{"issue":"Suppl 4","key":"10.1016\/j.seizure.2018.10.016_bib0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/epi.12567","article-title":"Lennox-Gastaut syndrome: a consensus approach to differential diagnosis","volume":"55","author":"Bourgeois","year":"2014","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2018.10.016_bib0095","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s00415-017-8535-7","article-title":"Understanding Lennox-Gastaut syndrome: insights from focal epilepsy patients with Lennox-Gastaut features","volume":"264","author":"Dupont","year":"2017","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2018.10.016_bib0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11530220-000000000-00000","article-title":"Medical management of Lennox-Gastaut syndrome","volume":"24","author":"Michoulas","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.seizure.2018.10.016_bib0105","article-title":"Treatment of lennox-gastaut syndrome","volume":"28","author":"Hancock","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.seizure.2018.10.016_bib0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2018.10.016_bib0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11530220-000000000-00000","article-title":"Medical management of Lennox- Gastaut syndrome","volume":"24","author":"Michoulas","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2018.10.016_bib0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1528-1157.1982.tb05085.x","article-title":"Sodium valproate: monotherapy and polytherapy","volume":"23","author":"Covanis","year":"1982","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.seizure.2018.10.016_bib0125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/adc.2009.165902","article-title":"A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period","volume":"95","author":"Anderson","year":"2010","journal-title":"Arch Dis Child"},{"issue":"7","key":"10.1016\/j.seizure.2018.10.016_bib0130","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1528-1167.2006.00587.x","article-title":"Valproate-associated coagulopathies are frequent and variable in children","volume":"47","author":"Gerstner","year":"2006","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1528-1157.2003.07202.x","article-title":"Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA","volume":"44","author":"Gopaul","year":"2003","journal-title":"Epilepsia"},{"issue":"1-2","key":"10.1016\/j.seizure.2018.10.016_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2007.09.012","article-title":"Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence","volume":"108","author":"Weisler","year":"2008","journal-title":"J Affect Disord"},{"issue":"25","key":"10.1016\/j.seizure.2018.10.016_bib0145","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJM199712183372504","article-title":"Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group","volume":"337","author":"Motte","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.seizure.2018.10.016_bib0150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1528-1157.1998.tb01411.x","article-title":"The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study","volume":"39","author":"Eriksson","year":"1998","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2018.10.016_bib0155","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1528-1157.1998.tb01413.x","article-title":"Lamotrigine and seizure aggravation in severe myoclonic epilepsy","volume":"39","author":"Guerrini","year":"1998","journal-title":"Epilepsia"},{"issue":"9566","key":"10.1016\/j.seizure.2018.10.016_bib0160","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.seizure.2018.10.016_bib0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007711","article-title":"Safety of lamotrigine in paediatrics: a systematic review","volume":"5","author":"Egunsola","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.seizure.2018.10.016_bib0170","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1528-1167.2006.00423.x","article-title":"Predictors of lamotrigine-associated rash","volume":"47","author":"Hirsch","year":"2006","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00007691-200106000-00006","article-title":"Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication","volume":"23","author":"Battino","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.seizure.2018.10.016_bib0180","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1992.tb04079.x","article-title":"Sodium valproate acutely inhibits lamotrigine metabolism","volume":"33","author":"Yuen","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2018.10.016_bib0185","first-page":"296","article-title":"The influence of rufinamide on sodium currents and action potential firing in rodent neurons","volume":"46","author":"McLean","year":"2005","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2018.10.016_bib0190","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejpn.2014.05.008","article-title":"Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines","volume":"18","author":"Coppola","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2018.10.016_bib0195","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.eplepsyres.2014.08.019","article-title":"Rufinamide as an adjunctive therapy for Lennox\u2013Gastaut syndrome: a randomized double-blind Placebo-controlled trial in Japan","volume":"108","author":"Ohtsuka","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2018.10.016_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.01.002","article-title":"Long- term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial","volume":"121","author":"Ohtsuka","year":"2016","journal-title":"Epilepsy Res"},{"issue":"21","key":"10.1016\/j.seizure.2018.10.016_bib0205","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-0404.2010.01334.x","article-title":"Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study","volume":"122","author":"Kluger","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2018.10.016_bib0215","article-title":"Rufinamide add-on therapy for refractory epilepsy","volume":"4","author":"Panebianco","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.seizure.2018.10.016_bib0220","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.seizure.2010.09.008","article-title":"Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience","volume":"19","author":"Coppola","year":"2010","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2018.10.016_bib0225","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.seizure.2012.02.006","article-title":"Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome","volume":"21","author":"Kim","year":"2012","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.seizure.2018.10.016_bib0230","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clineuro.2012.09.021","article-title":"Effectiveness and tolerability of rufinamide in children and young adults with Lennox- Gastaut syndrome: a single center study in Korea","volume":"115","author":"Lee","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.seizure.2018.10.016_bib0235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yebeh.2017.08.026","article-title":"Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: results from a European noninterventional registry study","volume":"76","author":"Nikanorova","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.seizure.2018.10.016_bib0240","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ejpn.2014.05.001","article-title":"Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0245","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejpn.2015.12.015","article-title":"Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study","volume":"20","author":"Arzimanoglou","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0250","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.seizure.2018.10.016_bib0255","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1212\/WNL.52.9.1882","article-title":"A doubleblind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group","volume":"52","author":"Sachdeo","year":"1999","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2018.10.016_bib0260","article-title":"Topiramate in Lennox- Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group","volume":"41","author":"Glauser","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.10.016_bib0265","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.seizure.2018.10.016_bib0270","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1684\/epd.2007.0144","article-title":"Treatment of pediatric epilepsy: european expert opinion","author":"Wheless","year":"2007","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2018.10.016_bib0275","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/088307380502000101","article-title":"Treatment of pediatric epilepsy: expert opinion","volume":"20","author":"Wheless","year":"2005","journal-title":"J Child Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2018.10.016_bib0280","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1177\/0883073800015001S05","article-title":"Safety and tolerability of topiramate in children","volume":"15","author":"Levisohn","year":"2000","journal-title":"J Child Neurol"},{"issue":"2-3","key":"10.1016\/j.seizure.2018.10.016_bib0285","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2006.06.020","article-title":"Felbamate: consensus of current clinical experience","volume":"71","author":"Pellock","year":"2006","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2018.10.016_bib0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/epd.2010.0303","article-title":"The evolution of antiepileptic drug development and regulation","volume":"12","author":"Arzimanoglou","year":"2010","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.seizure.2018.10.016_bib0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJM199301073280105","article-title":"The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome)","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"10.1016\/j.seizure.2018.10.016_bib0300","article-title":"Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-Month open-label study following a randomized clinical trial","volume":"34","author":"Dodson","year":"1993","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2018.10.016_bib0305","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/FPC.0000000000000327","article-title":"PharmGKB summary: clobazam pathway, pharmacokinetics","volume":"28","author":"Huddart","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.seizure.2018.10.016_bib0310","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0883073812463609","article-title":"Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes","volume":"28","author":"Wheless","year":"2013","journal-title":"J Child Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2018.10.016_bib0315","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":"Clobazam in the treatment of Lennox-Gastaut syndrome","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia"},{"issue":"15","key":"10.1016\/j.seizure.2018.10.016_bib0320","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2018.10.016_bib0325","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.12561","article-title":"Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years","volume":"55","author":"Conry","year":"2014","journal-title":"Epilepsia"},{"issue":"17","key":"10.1016\/j.seizure.2018.10.016_bib0330","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1212\/WNL.0000000000003253","article-title":"Deconstructing tolerance with clobazam: post hoc analyses from an open-label extension study","volume":"87","author":"Gidal","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2018.10.016_bib0335","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.yebeh.2017.10.003","article-title":"Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome","volume":"78","author":"Isojarvi","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2018.10.016_bib0340","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.pediatrneurol.2014.06.004","article-title":"Adjunctive levetira-cetam treatment in pediatric Lennox-Gastaut syndrome","volume":"51","author":"Kim","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2018.10.016_bib0345","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.braindev.2007.09.004","article-title":"Clinical efficacy of zonisamide in Lennox\u2013gastaut syndrome: Korean multicentric experience","volume":"30","author":"You","year":"2008","journal-title":"Brain Dev"},{"issue":"2","key":"10.1016\/j.seizure.2018.10.016_bib0350","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0035-1546276","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences","volume":"46","author":"Bir\u00f3","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.seizure.2018.10.016_bib0355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2017.05.036","article-title":"Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome","volume":"74","author":"Auvin","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0360","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1528-1167.2007.00983.x","article-title":"Pharmacokinetics and drug interactions with zonisamide","volume":"48","author":"Sills","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.10.016_bib0365","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2014.00011","article-title":"Mechanism of levetiracetam in the control of status epilepticus and epilepsy","volume":"5","author":"Deshpande","year":"2014","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2018.10.016_bib0370","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/0976-3147.203820","article-title":"Lennox-gastaut syndrome: a prospective follow-up study","volume":"8","author":"Rathaur","year":"2017","journal-title":"J Neurosci Rural Pract"},{"issue":"4","key":"10.1016\/j.seizure.2018.10.016_bib0375","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11910-016-0640-y","article-title":"Practice update: review of anticonvulsant therapy","volume":"16","author":"Chong","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"September","key":"10.1016\/j.seizure.2018.10.016_bib0380","article-title":"Individualized treatment approaches: fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome","volume":"27","author":"Polster","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.10.016_bib0385","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM198511283132219","article-title":"Treatment of self-induced photosensitive epilepsy with fenfluramine","volume":"313","author":"Aicardi","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2018.10.016_bib0390","first-page":"414","article-title":"Antiepileptic effects of fenfluramine: pilot study","volume":"22","author":"Gastaut","year":"1987","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2018.10.016_bib0395","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2007-973781","article-title":"Add-on therapy of fenfluramine in intractable self-induced epilepsy","volume":"27","author":"Boel","year":"1996","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.seizure.2018.10.016_bib0400","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.10.016_bib0405","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/epi.13407","article-title":"Five-year extended follow-up of 10 Dravet patients treated with fenfluramine","volume":"57","author":"Ceulemans","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.10.016_bib0410","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ene.13195","article-title":"Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients","volume":"24","author":"Schoonjans","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2018.10.016_bib0415","article-title":"ZX008 (fenfluramine HCl oral solution) in Dravet syndrome: results of a phase 3, randomized, double-blind, placebo-controlled trial","author":"Lagae","year":"2017","journal-title":"Presented at: 71st Annual Meeting of the American Epilepsy Society"},{"key":"10.1016\/j.seizure.2018.10.016_bib0420","first-page":"1","article-title":"A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome","volume":"00","author":"Lagae","year":"2018","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2018.10.016_bib0425","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results","volume":"59","author":"Szaflarski","year":"2018","journal-title":"Epilepsia"},{"issue":"10125","key":"10.1016\/j.seizure.2018.10.016_bib0430","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.seizure.2018.10.016_bib0435","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.seizure.2018.10.016_bib0440","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?","volume":"7","author":"Perucca","year":"2017","journal-title":"J Epilepsy Res"},{"issue":"5","key":"10.1016\/j.seizure.2018.10.016_bib0445","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1528-1157.1998.tb01413.x","article-title":"Lamotrigine and seizure aggravation in severe myoclonic epilepsy","volume":"38","author":"Guerrini","year":"1998","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2018.10.016_bib0450","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yebeh.2011.04.057","article-title":"Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome","volume":"21","author":"Mueller","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.seizure.2018.10.016_bib0455","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0920-1211(02)00010-4","article-title":"Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial","volume":"49","author":"Coppola","year":"2002","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.seizure.2018.10.016_bib0460","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/seiz.2000.0466","article-title":"Topiramate in the treatment of severe myoclonic epilepsy in infancy","volume":"9","author":"Nieto-Barrera","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.10.016_bib0465","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eplepsyres.2014.10.014","article-title":"Efficacy and tolerability of the ketogenic diet in Dravet syndrome\u2014 comparison with various standard antiepileptic drug regimen","volume":"109","author":"Dressler","year":"2015","journal-title":"Epilepsy Res"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118305508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118305508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:51:32Z","timestamp":1761011492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131118305508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":93,"alternative-id":["S1059131118305508"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2018.10.016","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacological management of Lennox-Gastaut syndrome and critical literature review","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2018.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}